DJIA 17,257.90 101.05 0.59%
NASDAQ 4,589.37 27.19 0.60%
S&P 500 2,009.54 7.97 0.40%
market minute promo

5.16 -0.16 (-3.01%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

PGNX $5.16 -3.01%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.39
Previous Close $5.32
Daily Range $5.20 - $5.42
52-Week Range $3.10 - $7.45
Market Cap $358.9M
P/E Ratio -8.72
Dividend (Yield) $0.00 (0.0%)
Volume 461,799
Average Daily Volume 913,301
Current FY EPS -$0.02

Sector

Healthcare

Industry

Drugs

Progenics Pharmaceuticals, Inc. (PGNX) Description

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Website: http://www.progenics.com/

News & Commentary

This Week in Biotech: AbbVie's Five-Leaf Clover and Exelixis' Excellent Results

A long-awaited mega-merger is announced, Exelixis reminds Wall Street that its pipeline is more than a single compound, and Amgen shows flashes of what's coming down its pipeline.

AstraZeneca's Constipation Drug Movantik Gets FDA Nod - Analyst Blog

2nd Half Of 2014 Biotechnology Catalysts--Part 4

Salix Pharmaceuticals Beats on Q2 Earnings, Cuts Guidance - Analyst Blog

US Stock Futures Signal Higher Start On Wall Street

Progenics Pharmaceuticals' (PGNX) CEO Mark Baker on Q2 2014 Results - Earnings Call Transcript

Progenics Pharmaceuticals (PGNX) Q2 2014 Results - Earnings Call Webcast

Earnings Scheduled For August 8, 2014

Will Progenics (PGNX) Disappoint this Earnings Season? - Analyst Blog

Progenics (PGNX) Shares March Higher, Can It Continue? - Tale of the Tape

Progenics (PGNX) Shares March Higher, Can It Continue? - Tale of the Tape

An Inefficient Stock Market Will Catch Up To Progenics

See More PGNX News...

PGNX's Top Competitors

PGNX $5.16 (-3.01%)
Current stock: PGNX
AMGN $141.35 (0.45%)
Current stock: AMGN
GILD $104.94 (1.06%)
Current stock: GILD
BIIB $328.04 (0.14%)
Current stock: BIIB